Cargando…
Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications
Introduction: Androgens have been described as important players in the regulation of vascular function/structure through their action on the release and effect of vasoactive factors, such as prostanoids. Patients with prostate cancer (PCa) under androgen deprivation therapies (ADTs) present increas...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076684/ https://www.ncbi.nlm.nih.gov/pubmed/33928136 http://dx.doi.org/10.3389/fcvm.2021.653126 |
_version_ | 1783684733523197952 |
---|---|
author | Álvarez-Maestro, Mario Eguibar, Aritz Chanca, Patricia Klett-Mingo, Mercedes Gómez Rivas, Juan Buño-Soto, Antonio de Bethencourt, Fermín R. Ferrer, Mercedes |
author_facet | Álvarez-Maestro, Mario Eguibar, Aritz Chanca, Patricia Klett-Mingo, Mercedes Gómez Rivas, Juan Buño-Soto, Antonio de Bethencourt, Fermín R. Ferrer, Mercedes |
author_sort | Álvarez-Maestro, Mario |
collection | PubMed |
description | Introduction: Androgens have been described as important players in the regulation of vascular function/structure through their action on the release and effect of vasoactive factors, such as prostanoids. Patients with prostate cancer (PCa) under androgen deprivation therapies (ADTs) present increased risk of cardiovascular mortality. Since thromboxane A(2) (TXA(2)) is one of the most studied prostanoids and its involvement in different cardiovascular diseases has been described, the aim of this study was to investigate: (i) the effect of ADT on the serum levels of TXA(2) in PCa patients and its possible link to the redox status and (ii) the effect of the non-hydrolyzable TXA(2) analog U-46619 on the function of the aorta of male rats. Methods: The levels of TXA(2) and total antioxidant status in 50 healthy subjects, 54 PCa patients, and 57 PCa under ADT were evaluated. These determinations were accompanied by levels of testosterone and C-reactive protein as an inflammation marker. In aortic segments from male rats, the U46619-induced effects on: (i) the vasomotor responses to acetylcholine (ACh), to the NO donor sodium nitroprusside (SNP), to the carbon monoxide-releasing molecule-3 (CORM-3), and to noradrenaline (NA) and (ii) the expression of cyclooxygenase-2 (COX-2), heme oxygenase-1 (HO-1), and phosphorylated ERK1/2 were analyzed. Results: The serum level of TXA(2) in patients with PCa was increased with respect to healthy subjects, which was further increased by ADT. There was no modification in the total antioxidant status among the three experimental groups. In aortic segments from male rats, the TXA(2) analog decreased the endothelium-dependent relaxation and the sensitivity of smooth muscle cells to NO, while it increased the vasoconstriction induced by NA; the expression of COX-2, HO-1, and pERK1/2 was also increased. Conclusions: ADT increased, along with other inflammatory/oxidative markers, the serum levels of TXA(2). The fact that TXA(2) negatively impacts the vascular function of the aorta of healthy male rats suggests that inhibition of TXA(2)-mediated events could be considered a potential strategy to protect the cardiovascular system. |
format | Online Article Text |
id | pubmed-8076684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80766842021-04-28 Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications Álvarez-Maestro, Mario Eguibar, Aritz Chanca, Patricia Klett-Mingo, Mercedes Gómez Rivas, Juan Buño-Soto, Antonio de Bethencourt, Fermín R. Ferrer, Mercedes Front Cardiovasc Med Cardiovascular Medicine Introduction: Androgens have been described as important players in the regulation of vascular function/structure through their action on the release and effect of vasoactive factors, such as prostanoids. Patients with prostate cancer (PCa) under androgen deprivation therapies (ADTs) present increased risk of cardiovascular mortality. Since thromboxane A(2) (TXA(2)) is one of the most studied prostanoids and its involvement in different cardiovascular diseases has been described, the aim of this study was to investigate: (i) the effect of ADT on the serum levels of TXA(2) in PCa patients and its possible link to the redox status and (ii) the effect of the non-hydrolyzable TXA(2) analog U-46619 on the function of the aorta of male rats. Methods: The levels of TXA(2) and total antioxidant status in 50 healthy subjects, 54 PCa patients, and 57 PCa under ADT were evaluated. These determinations were accompanied by levels of testosterone and C-reactive protein as an inflammation marker. In aortic segments from male rats, the U46619-induced effects on: (i) the vasomotor responses to acetylcholine (ACh), to the NO donor sodium nitroprusside (SNP), to the carbon monoxide-releasing molecule-3 (CORM-3), and to noradrenaline (NA) and (ii) the expression of cyclooxygenase-2 (COX-2), heme oxygenase-1 (HO-1), and phosphorylated ERK1/2 were analyzed. Results: The serum level of TXA(2) in patients with PCa was increased with respect to healthy subjects, which was further increased by ADT. There was no modification in the total antioxidant status among the three experimental groups. In aortic segments from male rats, the TXA(2) analog decreased the endothelium-dependent relaxation and the sensitivity of smooth muscle cells to NO, while it increased the vasoconstriction induced by NA; the expression of COX-2, HO-1, and pERK1/2 was also increased. Conclusions: ADT increased, along with other inflammatory/oxidative markers, the serum levels of TXA(2). The fact that TXA(2) negatively impacts the vascular function of the aorta of healthy male rats suggests that inhibition of TXA(2)-mediated events could be considered a potential strategy to protect the cardiovascular system. Frontiers Media S.A. 2021-04-13 /pmc/articles/PMC8076684/ /pubmed/33928136 http://dx.doi.org/10.3389/fcvm.2021.653126 Text en Copyright © 2021 Álvarez-Maestro, Eguibar, Chanca, Klett-Mingo, Gómez Rivas, Buño-Soto, de Bethencourt and Ferrer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Álvarez-Maestro, Mario Eguibar, Aritz Chanca, Patricia Klett-Mingo, Mercedes Gómez Rivas, Juan Buño-Soto, Antonio de Bethencourt, Fermín R. Ferrer, Mercedes Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications |
title | Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications |
title_full | Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications |
title_fullStr | Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications |
title_full_unstemmed | Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications |
title_short | Androgen Deprivation Therapy in Patients With Prostate Cancer Increases Serum Levels of Thromboxane A(2): Cardiovascular Implications |
title_sort | androgen deprivation therapy in patients with prostate cancer increases serum levels of thromboxane a(2): cardiovascular implications |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076684/ https://www.ncbi.nlm.nih.gov/pubmed/33928136 http://dx.doi.org/10.3389/fcvm.2021.653126 |
work_keys_str_mv | AT alvarezmaestromario androgendeprivationtherapyinpatientswithprostatecancerincreasesserumlevelsofthromboxanea2cardiovascularimplications AT eguibararitz androgendeprivationtherapyinpatientswithprostatecancerincreasesserumlevelsofthromboxanea2cardiovascularimplications AT chancapatricia androgendeprivationtherapyinpatientswithprostatecancerincreasesserumlevelsofthromboxanea2cardiovascularimplications AT klettmingomercedes androgendeprivationtherapyinpatientswithprostatecancerincreasesserumlevelsofthromboxanea2cardiovascularimplications AT gomezrivasjuan androgendeprivationtherapyinpatientswithprostatecancerincreasesserumlevelsofthromboxanea2cardiovascularimplications AT bunosotoantonio androgendeprivationtherapyinpatientswithprostatecancerincreasesserumlevelsofthromboxanea2cardiovascularimplications AT debethencourtferminr androgendeprivationtherapyinpatientswithprostatecancerincreasesserumlevelsofthromboxanea2cardiovascularimplications AT ferrermercedes androgendeprivationtherapyinpatientswithprostatecancerincreasesserumlevelsofthromboxanea2cardiovascularimplications |